quantisnow
FeedTopReportsPricing
⌘K
Live feed
20:49:52·56d
INSIDERFiling
BioMarin Pharmaceutical Inc. logo

EVP, Chief Technical Officer Guyer Charles Greg was granted 15,222 shares, increasing direct ownership by 19% to 96,439 units (SEC Form 4)

BMRN· BioMarin Pharmaceutical Inc.
Health Care
Original source

Companies

  • BMRN
    BioMarin Pharmaceutical Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$80.00
  • Jan 20UpdateCanaccord Genuity$98.00
  • Dec 3UpdateLeerink Partners$60.00
  • Nov 6UpdateStifel$61.00
  • Sep 8UpdateH.C. Wainwright$60.00
  • Sep 3UpdateRaymond James$85.00

Related

  • SEC9h
    SEC Form 8-K filed by BioMarin Pharmaceutical Inc.
  • PR2d
    BioMarin Announces Board Leadership Transition
  • SEC2d
    SEC Form DEFA14A filed by BioMarin Pharmaceutical Inc.
  • SEC2d
    SEC Form DEF 14A filed by BioMarin Pharmaceutical Inc.
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by BioMarin Pharmaceutical Inc.
  • INSIDER35d
    SEC Form 4 filed by Davis George Eric
  • INSIDER35d
    SEC Form 4 filed by Guyer Charles Greg
  • INSIDER35d
    SEC Form 4 filed by Mueller Brian
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022